Skin lymphoma is a type of cancer that starts in the white blood cells of the skin. Unlike lymphomas that begin in lymph nodes and later spread to the skin, primary cutaneous lymphoma originates in the skin itself. It develops when certain immune cells in the skin grow uncontrollably, forming patches, plaques, or tumors on the body’s surface. It accounts for roughly 4% of all non-Hodgkin lymphoma cases.
T-Cell vs. B-Cell Skin Lymphoma
Skin lymphomas are divided into two main categories based on which type of immune cell becomes cancerous. The more common form, cutaneous T-cell lymphoma (CTCL), involves T-cells, which normally help your body fight infections and abnormal cells. The less common form, cutaneous B-cell lymphoma (CBCL), involves B-cells, which are responsible for producing antibodies.
These two types behave differently under the skin. T-cell lymphomas tend to infiltrate the outermost layer of skin (the epidermis), which is why they often look like rashes or dry patches on the surface. B-cell lymphomas settle deeper in the skin’s middle layer (the dermis), typically forming firmer bumps or nodules. B-cell skin lymphomas generally follow a slower, more indolent course.
Mycosis Fungoides: The Most Common Type
Mycosis fungoides is the most common form of skin lymphoma, with roughly 8 to 9 cases per million people per year in the United States. Despite its name, it has nothing to do with a fungal infection. The disease typically progresses through three distinct stages, often over many years.
In the patch stage, flat, scaly patches appear on the skin. They can be reddish or brownish and tend to show up in areas usually covered by clothing, particularly the buttocks and upper thighs. These patches can range from a few centimeters across to larger than 6 centimeters, and they may look slightly thinned or discolored. Many people live with this stage for years or even decades before it progresses.
In the plaque stage, the patches become thicker and more raised, with well-defined edges. New lesions may appear, including on the face and scalp. They often take on a ring or horseshoe shape. In the tumor stage, firm reddish-purple nodules develop, each at least 1 centimeter across. The risk of the cancer spreading to lymph nodes or internal organs increases with each stage.
A more aggressive variant called Sézary syndrome involves widespread skin redness covering most of the body, swollen lymph nodes, and cancerous cells circulating in the bloodstream. Blood testing is critical to distinguish it from advanced mycosis fungoides.
Why It’s Often Mistaken for Eczema or Psoriasis
One of the most frustrating aspects of skin lymphoma is how closely it can resemble common, harmless skin conditions. Early-stage mycosis fungoides can look nearly identical to eczema, psoriasis, or other inflammatory rashes. In one well-documented case, a patient was treated for psoriasis for years before a biopsy revealed cutaneous T-cell lymphoma. The scaly patches that eventually led to diagnosis had been present for over 25 years.
Some features that may raise suspicion include patches that don’t respond to standard treatments, lesions in sun-protected areas rather than sun-exposed ones, and patches with a slightly violet tone rather than the bright red of typical eczema or psoriasis. But these differences can be subtle, and a skin biopsy is the only reliable way to tell the difference.
How Skin Lymphoma Is Diagnosed
Diagnosis starts with a skin biopsy, where a small sample of affected skin is examined under a microscope. Pathologists look for abnormal immune cells in characteristic patterns. For T-cell lymphomas, they look for cancerous T-cells migrating into the epidermis. For B-cell lymphomas, they look for dense clusters of abnormal B-cells in the dermis, which is notable because B-cells don’t normally accumulate in healthy skin.
A technique called immunophenotyping helps identify exactly which type of immune cell is involved by tagging cells with markers that light up under analysis. This can be done on preserved tissue samples or through flow cytometry, where individual cells are suspended in liquid and analyzed one by one. T-cell receptor gene rearrangement testing is another tool that detects whether T-cells share a common genetic origin, which would indicate they’re clones of a single cancerous cell rather than a normal mix of different immune cells.
Staging: How Far It Has Spread
Skin lymphoma uses a specialized staging system called TNMB, which stands for Tumor, Node, Metastasis, and Blood. The blood component is unique to skin lymphoma staging and reflects how important it is to know whether cancerous cells have entered the bloodstream.
- T (Tumor): Ranges from T1 (patches or plaques covering less than 10% of the body) to T4 (redness covering 80% or more of the body surface).
- N (Node): Ranges from N0 (no lymph node involvement) to N3 (central lymph nodes affected).
- M (Metastasis): M0 means no spread to internal organs; M1 means organs are involved.
- B (Blood): B0 means no significant cancer cells in the blood; B2 means a high number of circulating cancer cells.
These four components are combined to assign an overall stage from I to IV.
Who Gets Skin Lymphoma
CTCL is more common in men, who develop it at a rate of about 10 cases per million compared to about 7 per million in women. People aged 40 and older are six times more likely to be diagnosed than younger adults. Black Americans have the highest incidence of any racial or ethnic group at nearly 12 cases per million. The disease is also slightly more common in metropolitan areas and among people with higher socioeconomic status, though the reasons for these patterns aren’t fully understood.
Treatment for Early-Stage Disease
When skin lymphoma is caught early, treatment focuses directly on the skin rather than the whole body. Phototherapy, which uses ultraviolet light (either UVB or a combination treatment called PUVA), is one of the most established options and has strong long-term safety data. You would typically go for regular sessions where affected skin is exposed to controlled UV light.
Topical treatments applied directly to the skin are another first-line approach. These include prescription-strength corticosteroid creams and a chemotherapy gel containing nitrogen mustard, which has been used for this purpose since the late 1950s. For more widespread skin involvement, total skin electron beam therapy delivers a controlled dose of radiation across the entire skin surface. Following this with ongoing topical treatment can extend the time before the disease returns.
Treatment for Advanced Disease
When skin lymphoma progresses beyond the skin or doesn’t respond to skin-directed treatments, systemic therapies that work throughout the body become necessary. Two targeted antibody treatments have received FDA approval specifically for cutaneous T-cell lymphoma. One, approved in 2017, targets a protein called CD30 found on the surface of lymphoma cells. The other, approved in the US in 2018, targets a receptor called CCR4 and is used for patients who have already tried at least one other systemic treatment.
These targeted therapies represent a shift from older, broader chemotherapy approaches. They’re designed to seek out specific markers on cancer cells, which generally means fewer side effects than traditional chemotherapy.
Survival Rates by Stage
Prognosis varies dramatically depending on how advanced the disease is at diagnosis. For early-stage disease (stages I through IIA), the outlook is generally favorable. The 5-year survival rate for stage I is about 97%, and the 10-year survival rate for all early-stage patients exceeds 70%. Many people with early-stage mycosis fungoides live with the disease for decades, managing it as a chronic condition.
Advanced-stage disease (stages IIB through IVB) carries a significantly different prognosis. The 5-year survival rate drops to roughly 57% for stage III and 46% for stage IV. The 10-year survival rate for advanced-stage patients is under 30%. This sharp contrast underscores why early detection and accurate diagnosis matter so much.
Living With Persistent Itch
Severe itching is one of the most disruptive symptoms of cutaneous T-cell lymphoma, and it can significantly affect sleep, mood, and daily life. Treating the underlying lymphoma often helps, but when itching persists despite standard care, several additional options exist. Medications originally developed for nerve pain or nausea have shown benefit for lymphoma-related itch by interrupting the itch signals at different points in the nervous system. Some patients find relief with medications taken at bedtime that also promote sleep, addressing two problems at once. For the most resistant cases, drugs that block opioid receptors in the brain can help, since the body’s own opioid system plays a role in itch signaling.